Business Wire

IBC2018 Announces Telco and Media Innovation Forum amidst Plans for Record-Breaking Attendance

Jaa

IBC2018, the world’s most influential media, entertainment and technology show – which last year attracted more than 57,000 attendees from 170 countries – today announces an all-new Telco and Media Innovation Forum to expand its position as one of the preeminent destinations for telecoms and emerging technologies. The collaboration will form part of the prestigious annual IBC show at the RAI in Amsterdam from Thursday 13 to Tuesday 18 September 2018.

IBC2018’s focus on telecoms and smart connectivity comes at a time when the media and telecoms industries are becoming increasingly intertwined. Mirroring this trend, a cross-section of new and long-time IBC exhibitors will showcase the latest breakthroughs set to define both industries.

To reflect the ways in which emerging network technology is changing how the media world operates, IBC2018 will feature the dedicated Telco and Media Innovation Forum designed for the leading players in the industry and a new ‘Smart Connectivity and Multiplay Devices’ track within the IBC Conference Programme in order to provide a platform for collaborative dialogue between telecoms providers, media players and the OTT sector.

The exclusive Telco and Media Innovation Forum will include keynotes from Matt Stagg, Director of Mobile Strategy at BT Sport, Jeremy Fox, Co-founder & CEO, Atrium TV who will discuss how content is developing and how telecoms providers are benefitting from joining their club, and Domingo Corral Lopez, Director of Original Programming, Movistar who will give insight into how his business is developing original content under the wider Telefonica brand. This invitation-only programme will bring together C-suite level audience members to examine the collaboration between telecoms players and content providers, digital transformation, OTT content and current challenges around the evolution of the telecoms sector.

The ‘Smart Connectivity and Multiplay Devices’ track will tackle the challenges and opportunities offered by 5G, exploring the impact the technology will have on broadcasting and beyond. Speakers include Dr David Gomez-Barquero, Senior Researcher, Ramon & Cajal Fellow, Universitat Politecnica de Valencia and Dr Athul Prasad, Head of 5G Business Modelling & Analysis, Nokia - both from the 5G X-Cast consortium - who will deliver a focused masterclass on the future 5G network architecture for live scale immersive media delivery. Nicholas Wodtke, Executive VP, Digital Content, VEON will also give a case study around value added services, the role of content and how traditional mobile services are being disrupted.

IBC2018 is collaborating with the TM Forum - a non-profit industry association for service providers and their suppliers in the telecommunications sector - to increase cooperation and collaboration between their respective industries. TM Forum’s members generate over $2 trillion in revenue and serve five billion customers across 180 countries. The venture will encourage senior executives from both sectors to partner, helping broadcasters, operators and software vendors to work together across the media and telecoms sectors.

“IBC is the go-to destination for media technology professionals, attracting almost 60,000 people to Amsterdam each September. At IBC2018 we are launching the IBC Telco and Media Innovation Forum. Working with the TM Forum and others, IBC will to bring together C-level executives to explore the opportunities and challenges created by convergence,” said IBC CEO Michael Crimp. “We promise our hosted delegates a high-level networking event with world class content. I am sure this will be valuable day for all our guests. I am looking forward to being part of this new initiative.”

“Joining the biggest businesses in the telecoms and media spaces provides me with an opportunity to meet the most influential voices in each field – as a broadcaster looking at the role of mobile and our future, that’s vital,” commented Matt Stagg, Director of Mobile Strategy at BT Sport. “It’s important that events like this break down the silos of technologies and industries – this programme reflects the reality of broadcasting today.”

## ENDS ##

About IBC

IBC is the world’s most influential media, entertainment and technology show, attracting 57,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.

IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.

IBC2018 Dates

Conference:       13 - 17 September 2018
Exhibition: 14 - 18 September 2018

For more information about IBC2018 visit: show.ibc.org/

Contact information

Liberty Communications
Sophie Howell
IBC@libertycomms.com
+44 207 751 4444

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®20.5.2019 03:16:00 EESTTiedote

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019 Digestive Disease Week® (DDW) annual scientific meeting (May 18-21 in San Diego, CA), one of 18 Takeda sponsored vedolizumab abstracts accep

Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought19.5.2019 22:15:00 EESTTiedote

ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference. The study found significant differences in one-year adherence between people of different ages and disease severity levels: Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women. People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs. 70.4%). People with self-reported severe sleep apnea were 78% adherent at the one-year mark, compared to 70.5% of those with self-reported moderate sleep apnea, and 65.2% of those with mild sleep apnea. “Sleep specialists, pulmonologists, and primary care physicians should heed these results and ensure that their younger, female, and more mildly diagnosed patients have the proper supports to stay on therapy,” said Adam B

Workiva Named Best-In-Class Cloud Service Provider at UK Cloud Awards17.5.2019 15:00:00 EESTTiedote

Workiva (NYSE:WK), the leading cloud provider of connected data, reporting and compliance solutions, was named the Best-In-Class Cloud Service Provider by the UK Cloud Awards 2019 at a ceremony here last night. Now in its sixth year, the UK Cloud Awards recognise innovation and excellence in the cloud industry by showcasing leading companies, customers and individuals in the United Kingdom. Workiva was recognised for its Wdesk platform that helps organisations consolidate, connect and tag their data in a single, cloud environment so they are able to reduce risk and save time when filing reports with various regulators and other stakeholders. Workiva, the global leader in XBRL and Inline XBRL, is also streamlining how customers comply with the European Securities and Markets Authority's mandate for Inline XBRL for European Single Electronic Format (ESEF) reporting. More than 5,000 EU issuers will be required to use ESEF taxonomy for their annual financial reports, ending on or after Jan

Novaremed Presents Top-Line Results from Phase 2a Diabetic Neuropathic Pain Study of NRD.E1 at NeuPSIG 201917.5.2019 13:13:00 EESTTiedote

Novaremed AG, a clinical-stage Swiss biopharmaceutical company, today announced a poster presentation highlighting the top-line results from a Phase 2a (Proof of Concept) study of NRD.E1 for the treatment of diabetic neuropathic pain (DNP). The poster presentation took place at the 7th International Congress on Neuropathic Pain Meeting (NeuPSIG) in London, UK on May 9-11, 2019. “This was our first communication at a leading neuropathic pain-focused event. Novaremed’s lead drug, NRD.E1 is a non-opioid small molecule for the treatment of neuropathic pain. The results of our Phase 2a in patients with DNP showed clinically relevant treatment benefit from NRD.E1 across multiple primary and secondary endpoints, providing a strong scientific foundation for advancing the development of NRD.E1 into the upcoming global Phase 2b study in DNP,” said Sara Mangialaio, Head of R&D and Chief Medical Officer of Novaremed AG. “NRD.E1 has the potential to address a major unmet medical need in DNP.” Poste

WIN 2019 Symposium: WINnovation and Global Deployment of Precision Oncology17.5.2019 12:38:00 EESTTiedote

The 11th WIN Symposium in Precision Oncology will be held in Paris, France on June 23-24, 2019. ASCO® endorsed for the past 11 years, the WIN symposium will deliver an exciting line-up of speakers in Paris (France) on June 23-24, 2019 to discuss Innovation and Global Deployment of Precision Oncology. The current status of Precision Oncology across the globe will be examined with the exceptional participation of the chairmen of the event, Richard L. Schilsky, Chairman WIN Consortium(*), Senior Vice-President and Chief Medical Officer of ASCO, and Josep Tabernero, Vice Chairman WIN Consortium, President of ESMO and Director of Vall d’Hebron Institute of Oncology, Spain. Global experience will be shared: Optimizing Patient Enrollment and Efficacy of Precision Oncology Clinical Trials at UT MD Anderson Cancer Center, USA Decision Support for Precision Oncology: Evolving from Monotherapy to Genomically Informed Combinations, UT MD Anderson Cancer Center, USA The Value of Personalized Medici

Corsearch Acquires Principium Trademark Watch and Domain Services Businesses17.5.2019 11:00:00 EESTTiedote

Corsearch, the global brand creation, clearance, and protection leader, is pleased to announce the acquisition of the Principium Strategies trademark watch and domain services businesses, the brand protection subsidiary of Ladas and Parry LLP, a leader in global intellectual property law. The acquisition is effective immediately, solidifying and expanding Corsearch’s full-service trademark solutions offering for clients and brands globally. Principium is Corsearch’s third acquisition since becoming a standalone company in January 2018. The acquisition brings Corsearch’s employee count to more than 350 operating in 28 locations worldwide and adds valuable industry expertise and additional capabilities to Corsearch. “This is another really exciting acquisition for our business and a step forward in the evolution of Corsearch,” said Stephen Stolfi, Chief Commercial Officer of Corsearch. “Principium has provided clients with industry-leading trademark watching services for over 80 years an

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme